Anaesthesia makes up the largest hospital speciality and has a huge role to play in nearly every aspect of any hospital from operating theatres to accident and emergency, to the labour ward, and to intensive care. Our research ranges from basic molecular research into mechanisms of anaesthesia to investigating the clinical impact of novel anaesthetic agents.
Our research covers the entirety of patient’s perioperative journey and through this, we aim to deliver the greatest impact. The section has been pioneering in the development of novel technologies to facilitate the delivery of anaesthetic agents and has also made pivotal in-roads into the mechanism of action of anaesthetic agents and their wider application to other diseases (such as their protective roles in brain injury and in cancer).
@article{Dickinson:2010:10.1186/cc9051,
author = {Dickinson, R and Franks, NP},
doi = {10.1186/cc9051},
journal = {Critical Care},
title = {Bench-to-bedside review: molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection},
url = {http://dx.doi.org/10.1186/cc9051},
volume = {14},
year = {2010}
}
TY - JOUR
AB - In the past decade there has been a resurgence of interest in the clinical use of inert gases. In the present paper we review the use of inert gases as anesthetics and neuroprotectants, with particular attention to the clinical use of xenon. We discuss recent advances in understanding the molecular pharmacology of xenon and we highlight specific pharmacological targets that may mediate its actions as an anesthetic and neuroprotectant. We summarize recent in vitro and in vivo studies on the actions of helium and the other inert gases, and discuss their potential to be used as neuroprotective agents.
AU - Dickinson,R
AU - Franks,NP
DO - 10.1186/cc9051
PY - 2010///
SN - 1364-8535
TI - Bench-to-bedside review: molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection
T2 - Critical Care
UR - http://dx.doi.org/10.1186/cc9051
UR - http://hdl.handle.net/10044/1/32931
VL - 14
ER -